inhibitor

(redirected from nucleoside reverse transcriptase inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
See: deterrent
References in periodicals archive ?
A recent study from southern India showed if viral load monitoring is not available, severe resistance mutations occur to the current first line HAART regimens and these might jeopardize future second line nucleoside reverse transcriptase inhibitors (NRTI) drugs (tenofovir, abacavir, didanosine) and also the newer non NRTI (NNRTI) drugs (etravirine and TMC278) under development.
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients The SMART/INSIGHT and DAD Study Groups AIDS, 2008, 22, F17-F24
The guidelines advocate initial treatment regimens that consist of two nucleoside reverse transcriptase inhibitors (NRTIs) plus either the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz or a ritonavir-boosted protease inhibitor (PI/r).
Nucleotide analogs do not require as much phosphorylation in the host's cells as the nucleoside reverse transcriptase inhibitors to become active drugs.
Other studies suggest that the use of PIs and another class of antiviral drugs--the nucleoside reverse transcriptase inhibitors (NRTIs)--are also associated with atherosclerosis, liver problems, pancreatitis, and peripheral neuropathy.
The three classes include: nucleoside reverse transcriptase inhibitors (NRTIs); protease inhibitors (PIs); and the newest class, non-nucleoside reverse transcriptase inhibitors (NNRTIs).
The mechanism of action for this nucleotide analogue is different from other nucleoside reverse transcriptase inhibitors. To become activated, the nucleoside analogue drugs must be phosphorylated by a series of cellular kinases.
The Column A agents must be used in combination with two nucleoside reverse transcriptase inhibitors (NRTIs).
The phase III ATLAS study met its primary endpoint, with cabotegravir and rilpivirine demonstrating non-inferiority to an oral three-drug regimen of two nucleoside reverse transcriptase inhibitors plus a third agent, as measured by the proportion of participants with plasma HIV-1 RNA greater than or equal to50 copies per millilitre using the FDA Snapshot algorithm at Week 48.
The studies found high rates of virologic suppression with Biktarvy in treatment-experienced adults, regardless of pre-existing resistance to nucleoside reverse transcriptase inhibitors (NRTIs).
The current standard treatment involves a three-drug regimen of dolutegravir and two nucleoside reverse transcriptase inhibitors.
The study randomised 716 adults with HIV infection to receive antiretroviral treatment with efavirenz or nevirapine plus two nucleoside reverse transcriptase inhibitors (NRTIs).

Full browser ?